The CAR-T cell therapy market is likely to grow from USD 4.6 billion in 2024 to reach USD 5.1 billion in 2025 and USD 15.2 billion by 2035, representing a CAGR of 11.4% during the forecast period.
CAR-T cell therapy, amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR T therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally.
Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html
Competitive Landscape of CAR-T Cell Therapy Market
CAR-T cell therapy is among the most promising domains in the healthcare industry. Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. In January 2024, Kite Pharma achieves a milestone with the FDA's approval of their advancement in manufacturing process for axicabtagene ciloleucel (Yescarta®), significantly eliminating the median turnaround time.
CAR-T Cell Therapy Market Regional Outlook
Based on the regional distribution, North America held more than 65% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption. By 2035, Asia Pacific is likely to capture more than 24% share of the global market share. However, in 2024 Yescarta (Axicabtagene Ciloleucel) became the first CAR T cell therapy to receive approval from NICE to be provided to the patients through NHS. As such, the Asia Pacific market will continue to grow at a healthy CAGR during the forecast period.
CAR-T Cell Therapy Market Segments
Based on the research, Roots Analysis has segmented the CAR-T cell therapy Market into Type of Target Antigen, Type of Target Indication, Key Geographical Regions, Sales Forecast of CAR-T cell Therapies and Leading Players.
CAR-T Cell Therapy Market, by Type of Target Antigen
- CD 19
- B-cell Maturation Antigen (BCMA)
- CD 20
- CD 19/22
- Other Target Antigens
CAR-T Cell Therapy Market, by Type of Target Indication
- Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Others
CAR-T Cell Therapy Market, by Key Geographical Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
CAR-T Cell Therapy Market, Sales Forecast
- Approved Therapies
- Clinical Stage Therapies (Phase II and above)
CAR-T Cell Therapy Market, by Leading Players
- Gilead Sciences
- Bristol Myers Squibb
- Novartis
- Janssen
- JW Therapeutics
About Roots Analysis
Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors.
Why Use Roots Analysis in era of Artificial Intelligence?
- Tailored Insights
- Robust Methodology
- Smart Decisions Made Easy
By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry.
Services Offered:
- Consulting Services (custom insights supporting strategic and tactical requirements, off-the-shelf ready to consume work)
Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors.
They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans.
Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation.
- Subscription Services (bundled services supporting multiple topics and domains for a firm)
With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats.
The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively.
Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights.
Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
Comments
0 comment